文献速递炎症性肠病胃肠动力与功能性疾病

微生物-牛磺酸通路连接膳食纤维与黏膜愈合

Microbiota-Taurine Pathway Links Dietary Fiber to Mucosal Healing.
PubMed 文献 · Gastroenterology · 2026-10-21

该研究在DSS诱导的小鼠结肠炎中筛选纤维,发现藻酸盐通过富集释放牛磺酸的细菌、增加肠道牛磺酸并诱导上皮Cyp2c55促进黏膜修复;在UC患者的随机对照试验中,主要终点未达到,但藻酸盐补充与粪便牛磺酸水平及结肠CYP2C18表达等生物学变化相关。

要点

  • 藻酸盐通过微生物依赖的牛磺酸-上皮Cyp2c55通路促进小鼠结肠炎恢复。
  • 抗生素破坏菌群或敲除Slc6a6、Cyp2c55均消除藻酸盐的保护作用。
  • UC临床试验主要终点未达到,但观察到与临床前机制一致的生物学变化。

核心结论

  • 藻酸盐激活纤维-微生物-牛磺酸-上皮信号通路,在临床前模型中促进结肠炎恢复。
  • UC临床试验未达到主要终点,但生物学变化值得进一步研究藻酸盐作为微生物靶向干预。

研究设计与样本

  • 在DSS诱导的小鼠结肠炎中筛选纤维,评估生存、炎症、屏障功能和上皮再生。
  • 使用抗生素和细菌补充评估微生物依赖性,采用CE-TOFMS代谢物分析、RNA-seq和结肠类器官损伤实验。
  • 使用Slc6a6-/-和Cyp2c55-/-小鼠确定机制需求。
  • 在UC患者中开展随机安慰剂对照试验,患者接受抗生素预处理粪菌移植(A-FMT)后给予藻酸盐或安慰剂。

主要发现

  • 藻酸盐改善DSS结肠炎恢复,减轻炎症、恢复屏障完整性并增强隐窝增殖。
  • 藻酸盐富集释放牛磺酸的细菌(包括Bacteroides acidifaciens和Ligilactobacillus murinus)并增加肠道牛磺酸;抗生素破坏消除这些效应。
  • 牛磺酸是获益所必需,藻酸盐在Slc6a6-/-小鼠中失效。
  • 藻酸盐和牛磺酸诱导上皮Cyp2c55,保护作用在Cyp2c55-/-小鼠和类器官中丧失。
  • 临床试验主要终点未达到,但藻酸盐补充与粪便牛磺酸水平和结肠CYP2C18表达等生物学变化相关。

关键数值与推荐

  • 临床试验主要终点未达到。
  • 藻酸盐补充与粪便牛磺酸水平及结肠CYP2C18表达变化相关。

临床怎么用

  • 藻酸盐可能作为微生物靶向干预用于促进UC黏膜愈合,但需进一步临床验证。
  • 监测粪便牛磺酸和结肠CYP2C18表达可能有助于评估生物学效应。

局限性

  • 临床前机制主要来自小鼠模型,人体证据有限。
  • UC临床试验主要终点未达到,临床获益未证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Dietary fibers modulate host-microbiota interactions. Whether fiber promotes epithelial repair through microbiota-dependent mechanisms remains unclear. We determined how alginate influences colitis recovery and whether the pathway is relevant to ulcerative colitis (UC). METHODS: We screened fibers in dextran sodium sulfate (DSS)-induced murine colitis and assessed survival, inflammation, barrier function, and epithelial regeneration. Microbiota dependence was evaluated using antibiotics and bacterial supplementation. Metabolites were profiled using capillary electrophoresis-time-of-flight mass spectrometry (CE-TOFMS), and epithelial programs were analyzed using RNA-seq and colonic organoid injury assays. Slc6a6-/- and Cyp2c55-/- mice were used to determine mechanistic requirements. Translational relevance was examined in a randomized, placebo-controlled trial of UC patients receiving antibiotic-primed fecal microbiota transplantation (A-FMT) followed by alginate or placebo. Clinical outcomes, histology, fecal taurine, and colonic CYP2C18 expression were assessed. RESULTS: Alginate improved DSS colitis recovery, reducing inflammation, restoring barrier integrity, and enhancing crypt proliferation. Alginate enriched taurine-releasing bacteria, including Bacteroides acidifaciens and Ligilactobacillus murinus, and increased intestinal taurine; antibiotic disruption abrogated these effects. Taurine was required for benefit, as alginate failed in Slc6a6-/- mice. Alginate and taurine induced epithelial Cyp2c55, and protection was lost in Cyp2c55-/- mice and organoids. In the clinical trial, the primary endpoint was not met. However, alginate supplementation was associated with biological changes, including fecal taurine levels and colonic CYP2C18 expression, consistent with preclinical mechanisms. CONCLUSION: Alginate engages a fiber-microbiota-taurine-epithelial signaling pathway that promotes recovery in preclinical models. The clinical trial did not meet its primary endpoint; however, the biological changes warrant further investigation of alginate as a microbiota-targeted intervention. CLINICAL TRIAL REGISTRY: jRCTs031200103 (https://jrct.mhlw.go.jp/), registered September 1, 2020: UMIN000041968 (https://www.umin.ac.jp/ctr/index.htm), October 1, 2020.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Odakura R, Seki N, Nomura K, et al. Microbiota-Taurine Pathway Links Dietary Fiber to Mucosal Healing. Gastroenterology. 2026. PMID: 42906827. doi:10.1053/j.gastro.2026.09.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。